文献速递新发突发、热带与寄生虫病艾滋病与性传播感染

淋球菌疫苗有望快速降低城市男男性行为者淋病奈瑟菌感染发病率

A Gonococcal Vaccine Has the Potential to Rapidly Reduce the Incidence of Neisseria gonorrhoeae Infection Among Urban Men Who Have Sex With Men.
PubMed 文献 · J Infect Dis · 2022-01-01

研究采用个体水平、解剖部位特异性数学模型模拟10000名男男性行为者(MSM)中淋病奈瑟菌传播。结果显示,若30%的MSM在性传播感染检测就诊时接种疫苗,100%或50%保护效力的疫苗可在2年内使淋病患病率分别降低94%或62%;≥50%效力且持续2年的疫苗在平均每3年接种加强针条件下可能8年内消除淋病。

要点

  • 30%MSM接种时,100%效力疫苗2年内降低患病率94%,50%效力降低62%。
  • ≥50%效力持续2年疫苗加每3年平均加强接种,可能8年内消除淋病。
  • 疫苗若并非所有解剖部位均有效,其影响可能降低。

核心结论

  • 针对就诊于性传播感染筛查的MSM接种中等效力疫苗,可快速大幅降低该人群淋病患病率。

研究设计与样本

  • 个体水平、解剖部位特异性数学模型,模拟10000名MSM中淋病奈瑟菌传播,评估疫苗接种对淋病患病率的影响。

主要发现

  • 100%保护效力疫苗且30%MSM接种时,2年内淋病患病率降低94%。
  • 50%保护效力疫苗且30%MSM接种时,2年内淋病患病率降低62%。
  • ≥50%效力且持续2年的疫苗,在平均每3年接种加强针条件下,可能8年内消除淋病。
  • 疫苗若并非所有解剖部位均有效,其影响可能降低。

临床怎么用

  • 原文结论认为,以就诊于性传播感染筛查的MSM为免疫策略目标人群,接种中等效力疫苗可快速大幅降低淋病患病率。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A gonococcal vaccine is urgently needed due to increasing gonorrhea incidence and emerging multidrug-resistant gonococcal strains worldwide. Men who have sex with men (MSM) have among the highest incidences of gonorrhea and may be a key target population for vaccination when available. METHODS: An individual-based, anatomical site-specific mathematical model was used to simulate Neisseria gonorrhoeae transmission in a population of 10 000 MSM. The impact of vaccination on gonorrhea prevalence was assessed. RESULTS: With a gonococcal vaccine of 100% or 50% protective efficacy, gonorrhea prevalence could be reduced by 94% or 62%, respectively, within 2 years if 30% of MSM are vaccinated on presentation for sexually transmitted infection (STI) testing. Elimination of gonorrhea is possible within 8 years with vaccines of ≥ 50% efficacy lasting 2 years, providing a booster vaccination is available every 3 years on average. A vaccine's impact may be reduced if it is not effective at all anatomical sites. CONCLUSIONS: Our study indicates that with a vaccine of modest efficacy and an immunization strategy that targets MSM presenting for STI screening, the prevalence of gonorrhea in this population could be rapidly and substantially reduced.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Hui BB, Padeniya TN, Rebuli N, et al. A Gonococcal Vaccine Has the Potential to Rapidly Reduce the Incidence of Neisseria gonorrhoeae Infection Among Urban Men Who Have Sex With Men. J Infect Dis. 2022. PMID: 34894134. doi:10.1093/infdis/jiab581

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。